The company develops antiviral therapeutics using drug-like compounds to target a key HPV protein expressed in early, pre-malignant, and cancerous pathologies, with the goal of treating patients infected with HPV. Kovina Therapeutics is currently at the preclinical stage of developing first-in-class antiviral therapeutics designed to treat cancers and pre-malignant infections caused by HPV.